Theracryf Plc
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and n… Read more
Theracryf Plc (TCF) - Total Liabilities
Latest total liabilities as of September 2025: GBX1.82 Million GBX
Based on the latest financial reports, Theracryf Plc (TCF) has total liabilities worth GBX1.82 Million GBX as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Theracryf Plc - Total Liabilities Trend (2017–2025)
This chart illustrates how Theracryf Plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Theracryf Plc Competitors by Total Liabilities
The table below lists competitors of Theracryf Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Restart Life Sciences Corp.
PINK:NMLSD
|
USA | $214.89K |
|
Neovacs S.A.
PA:ALNEV
|
France | €4.18 Million |
|
Reem Capital Corp.
V:REEM-P
|
Canada | CA$82.37K |
|
CANADA ZINC METALS
MU:M9R
|
Germany | €1.47 Million |
|
SOLOMON SYSTECH
MU:RZF
|
Germany | €30.50 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Theracryf Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theracryf Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theracryf Plc (2017–2025)
The table below shows the annual total liabilities of Theracryf Plc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | GBX1.66 Million | +130.37% |
| 2024-03-31 | GBX721.00K | -13.45% |
| 2023-03-31 | GBX833.00K | +102.68% |
| 2022-03-31 | GBX411.00K | -32.29% |
| 2021-03-31 | GBX607.00K | -7.04% |
| 2020-03-31 | GBX653.00K | -5.09% |
| 2019-03-31 | GBX688.00K | +76.86% |
| 2018-03-31 | GBX389.00K | -24.32% |
| 2017-03-31 | GBX514.00K | -- |